| MOTOLIMOD | Small molecule | ovarian cancer | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| BAZLITORAN | Unknown | Waldenstrom macroglobulinemia | Toll-like receptor 8 antagonist | 1.0 | Terminated | ClinicalTrials |
| MOTOLIMOD | Small molecule | fallopian tube cancer | Toll-like receptor 8 agonist | 2.0 | Completed | ClinicalTrials |
| SELGANTOLIMOD | Small molecule | chronic hepatitis B virus infection | Toll-like receptor 8 agonist | 2.0 | Recruiting | ClinicalTrials |
| ENPATORAN | Small molecule | systemic lupus erythematosus | Toll-like receptor 8 antagonist | 1.0 | Recruiting | ClinicalTrials |
| BAZLITORAN | Unknown | psoriasis | Toll-like receptor 8 antagonist | 2.0 | Completed | ClinicalTrials |
| MOTOLIMOD | Small molecule | lymphoma | Toll-like receptor 8 agonist | 1.0 | Terminated | ClinicalTrials |
| ENPATORAN | Small molecule | COVID-19 | Toll-like receptor 8 antagonist | 2.0 | Completed | ClinicalTrials |
| MOTOLIMOD | Small molecule | head and neck squamous cell carcinoma | Toll-like receptor 8 agonist | 0.5 | Terminated | ClinicalTrials |
| RESIQUIMOD | Small molecule | cutaneous melanoma | Toll-like receptor 8 agonist | 0.5 | Completed | ClinicalTrials |
| MOTOLIMOD | Small molecule | nasal cavity and paranasal sinus squamous cell carcinoma | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | mucosal melanoma | Toll-like receptor 8 agonist | 1.0 | Unknown status | ClinicalTrials |
| MOTOLIMOD | Small molecule | tongue neoplasm | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| MOTOLIMOD | Small molecule | ovarian cancer | Toll-like receptor 8 agonist | 2.0 | Completed | ClinicalTrials |
| MOTOLIMOD | Small molecule | laryngeal squamous cell carcinoma | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| BAZLITORAN | Unknown | dermatomyositis | Toll-like receptor 8 antagonist | 2.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | hepatitis B virus infection | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | basal cell carcinoma | Toll-like receptor 8 agonist | 1.0 | Terminated | ClinicalTrials |
| MOTOLIMOD | Small molecule | lymphoma | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | cancer | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| MOTOLIMOD | Small molecule | primary peritoneal carcinoma | Toll-like receptor 8 agonist | 2.0 | Completed | ClinicalTrials |
| MOTOLIMOD | Small molecule | head and neck squamous cell carcinoma | Toll-like receptor 8 agonist | 1.0 | Terminated | ClinicalTrials |
| RESIQUIMOD | Small molecule | Cutaneous T-cell lymphoma | Toll-like receptor 8 agonist | 2.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | Cutaneous T-cell lymphoma | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| ENPATORAN | Small molecule | systemic lupus erythematosus | Toll-like receptor 8 antagonist | 2.0 | Recruiting | ClinicalTrials |
| RESIQUIMOD | Small molecule | influenza | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | oligodendroglioma | Toll-like receptor 8 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| MOTOLIMOD | Small molecule | hypopharyngeal carcinoma | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| ENPATORAN | Small molecule | cutaneous lupus erythematosus | Toll-like receptor 8 antagonist | 1.0 | Recruiting | ClinicalTrials |
| BAZLITORAN | Unknown | diffuse large B-cell lymphoma | Toll-like receptor 8 antagonist | 1.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | glioblastoma multiforme | Toll-like receptor 8 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| MOTOLIMOD | Small molecule | verrucous carcinoma | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| MOTOLIMOD | Small molecule | oropharyngeal carcinoma | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| TELRATOLIMOD | Small molecule | HIV infection | Toll-like receptor 8 agonist | 1.0 | Recruiting | ClinicalTrials |
| MOTOLIMOD | Small molecule | salivary gland squamous cell carcinoma | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | melanoma | Toll-like receptor 8 agonist | 0.5 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | metastatic melanoma | Toll-like receptor 8 agonist | 1.0 | Unknown status | ClinicalTrials |
| RESIQUIMOD | Small molecule | melanoma | Toll-like receptor 8 agonist | 2.0 | Completed | ClinicalTrials |
| BAZLITORAN | Unknown | Waldenstrom macroglobulinemia | Toll-like receptor 8 antagonist | 1.0 | Completed | ClinicalTrials |
| TELRATOLIMOD | Small molecule | Cutaneous T-cell lymphoma | Toll-like receptor 8 agonist | 1.0 | Terminated | ClinicalTrials |
| RESIQUIMOD | Small molecule | actinic keratosis | Toll-like receptor 8 agonist | 2.0 | Completed | ClinicalTrials |
| SELGANTOLIMOD | Small molecule | chronic hepatitis B virus infection | Toll-like receptor 8 agonist | 2.0 | Completed | ClinicalTrials |
| MOTOLIMOD | Small molecule | squamous cell carcinoma | Toll-like receptor 8 agonist | 2.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | anaplastic astrocytoma | Toll-like receptor 8 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| MOTOLIMOD | Small molecule | squamous cell carcinoma | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | neoplasm | Toll-like receptor 8 agonist | 1.0 | Completed | ClinicalTrials |